DENTSPLY SIRONA (XRAY) Stock Overview
Develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for XRAY from our risk checks.
XRAY Community Fair Values
Create NarrativeSee what 21 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$45.5
FV
74.1% undervalued intrinsic discount73
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
DENTSPLY SIRONA Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.78 |
| 52 Week High | US$17.09 |
| 52 Week Low | US$9.41 |
| Beta | 0.89 |
| 1 Month Change | 14.81% |
| 3 Month Change | -0.67% |
| 1 Year Change | -28.91% |
| 3 Year Change | -71.15% |
| 5 Year Change | -81.05% |
| Change since IPO | 1,587.88% |
Recent News & Updates
Seeking Alpha • Jul 07
Dentsply Sirona: The Recovery Story Needs More Than A Stock Rebound
Summary DENTSPLY SIRONA is on a conditional recovery watch, rated Hold with a bullish bias, pending clear evidence of turnaround. XRAY’s Q1 2026 saw constant-currency sales decline 6.7%, adjusted EBITDA margin drop to 14.7%, and negative free cash flow of $12 million. Management’s 2026 guidance is optimistic, but upside depends on sustained sales momentum, positive FCF, and net debt reduction. Valuation appears low versus peers, but the discount is justified until operating and financial improvements are demonstrated. Read the full article on Seeking Alpha
Narrative Update • Jun 29
XRAY: Reset Expectations And Product Execution Will Shape 2026 Rebound Potential
The analyst price target for DENTSPLY SIRONA has been lowered from $14.54 to $13.40 as analysts, citing a series of reduced targets from firms including Barclays, Mizuho, Citi and Evercore ISI, reassessed the stock with updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. Analyst Commentary Recent Street research around DENTSPLY SIRONA points to a cautious stance, with several firms trimming price targets and highlighting execution and valuation risks.Analysis Article • Jun 18
DENTSPLY SIRONA (XRAY) Stock Could Be 78% Undervalued After CFO Appointment
DENTSPLY SIRONA (XRAY) is back in focus after the company appointed John C. Fortson as Chief Financial Officer and Executive Vice President, a leadership change that could influence how investors view the stock. See our latest analysis for DENTSPLY SIRONA. The latest leadership news arrives after a tough stretch for DENTSPLY SIRONA. The share price is down 11% year to date and the 1 year total shareholder return has fallen 32.4%, pointing to fading momentum despite a modest 2.1% 1 month share...
Narrative Update • Jun 15
XRAY: Lowered Fair Value And Execution Risks Will Pressure Risk Reward
DENTSPLY SIRONA's analyst price target has adjusted from $10.00 to $9.00 as analysts incorporate updated assumptions for fair value, discount rate, revenue growth, profit margins and future P/E following a series of recent bearish target cuts. Analyst Commentary Recent research updates on DENTSPLY SIRONA have leaned cautious, with several bearish analysts revising their fair value assumptions and lowering price targets.Recent updates
Seeking Alpha • Jul 07
Dentsply Sirona: The Recovery Story Needs More Than A Stock Rebound
Summary DENTSPLY SIRONA is on a conditional recovery watch, rated Hold with a bullish bias, pending clear evidence of turnaround. XRAY’s Q1 2026 saw constant-currency sales decline 6.7%, adjusted EBITDA margin drop to 14.7%, and negative free cash flow of $12 million. Management’s 2026 guidance is optimistic, but upside depends on sustained sales momentum, positive FCF, and net debt reduction. Valuation appears low versus peers, but the discount is justified until operating and financial improvements are demonstrated. Read the full article on Seeking AlphaNarrative Update • Jun 29
XRAY: Reset Expectations And Product Execution Will Shape 2026 Rebound Potential
The analyst price target for DENTSPLY SIRONA has been lowered from $14.54 to $13.40 as analysts, citing a series of reduced targets from firms including Barclays, Mizuho, Citi and Evercore ISI, reassessed the stock with updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. Analyst Commentary Recent Street research around DENTSPLY SIRONA points to a cautious stance, with several firms trimming price targets and highlighting execution and valuation risks.Analysis Article • Jun 18
DENTSPLY SIRONA (XRAY) Stock Could Be 78% Undervalued After CFO Appointment
DENTSPLY SIRONA (XRAY) is back in focus after the company appointed John C. Fortson as Chief Financial Officer and Executive Vice President, a leadership change that could influence how investors view the stock. See our latest analysis for DENTSPLY SIRONA. The latest leadership news arrives after a tough stretch for DENTSPLY SIRONA. The share price is down 11% year to date and the 1 year total shareholder return has fallen 32.4%, pointing to fading momentum despite a modest 2.1% 1 month share...Narrative Update • Jun 15
XRAY: Lowered Fair Value And Execution Risks Will Pressure Risk Reward
DENTSPLY SIRONA's analyst price target has adjusted from $10.00 to $9.00 as analysts incorporate updated assumptions for fair value, discount rate, revenue growth, profit margins and future P/E following a series of recent bearish target cuts. Analyst Commentary Recent research updates on DENTSPLY SIRONA have leaned cautious, with several bearish analysts revising their fair value assumptions and lowering price targets.
Narrative Update • Jun 01
XRAY: New Tech Partnerships And Cost Discipline Will Support Future Upside
The analyst price target for DENTSPLY SIRONA has been adjusted from $18.00 to $17.00, with analysts citing updated assumptions on revenue growth, profit margins, future P/E, and recent cautious Street research. Analyst Commentary Recent Street research on DENTSPLY SIRONA has centered on revised price targets and cautious initial views, with analysts reassessing assumptions around revenue growth, profitability, and valuation multiples.Narrative Update • May 02
XRAY: Execution Risks And Impairments Will Continue To Pressure Risk Reward
The analyst price target for DENTSPLY SIRONA has been revised to reflect mixed Street views, with recent changes in the $14 to $18 range as analysts factor in updated expectations for revenue growth, profit margins, and valuation multiples following the latest company updates. Analyst Commentary Analyst sentiment on DENTSPLY SIRONA is mixed, with several recent research updates clustering in the mid teens price target range.Narrative Update • Apr 18
XRAY: Ongoing Execution Setbacks And Impairments Will Pressure Risk Reward Outlook
The analyst price target for DENTSPLY SIRONA has been reduced by $1 to $10.00, as analysts factor in a higher discount rate, a lower assumed revenue growth rate, improved margin expectations, and a lower future P/E multiple following a mix of recent bearish and more constructive research updates. Analyst Commentary Recent Street research on DENTSPLY SIRONA combines cautious initiation with a series of price target revisions around the Q4 report, creating a mixed backdrop for sentiment and valuation.Narrative Update • Apr 04
XRAY: Dental Market Stabilization And New Technology Partnerships Will Support Upside
DENTSPLY SIRONA's updated analyst price target of $18, up from $16, reflects analysts' refreshed models following the Q4 report, with several firms pointing to signs of dental market stabilization even as they reassess growth, margins, discount rates, and future P/E assumptions. Analyst Commentary Recent Street research around DENTSPLY SIRONA has centered on refreshed models following the Q4 report, with bullish analysts adjusting their price targets as they reassess assumptions on growth, margins, discount rates, and future P/E levels.Narrative Update • Mar 21
XRAY: Dental Market Stabilisation And Q4 Model Resets Will Shape 2026 Outlook
Analysts have nudged the DENTSPLY SIRONA price target higher to $14.54 from $14.43, reflecting updated models that factor in revised revenue growth assumptions, a slightly lower profit margin outlook, a modestly higher future P/E expectation, and recent Street research citing signs of dental market stabilisation alongside refreshed views following the Q4 report. Analyst Commentary Recent Street research around DENTSPLY SIRONA has focused on refreshed price targets, updated models after the Q4 report, and early signs that the dental market may be stabilizing.Narrative Update • Mar 07
XRAY: Dental Market Stabilization And Idea List Inclusion Will Shape 2026 Outlook
The Analyst Price Target for DENTSPLY SIRONA has moved higher from $12.97 to $14.43 as analysts factor in updated post Q4 models, slightly improved margin assumptions, and what they describe as early signs of stabilization in the dental market. Analyst Commentary Recent Street research shows a cluster of upward price target revisions for DENTSPLY SIRONA following the Q4 report, with analysts updating models and reassessing the risk and reward trade off.Narrative Update • Feb 20
XRAY: Execution Risks And CFO Transition Will Pressure Risk Reward Outlook
Analysts have made a modest adjustment to their $11.00 fair value estimate for DENTSPLY SIRONA, reflecting updated assumptions around discount rates, revenue growth, profit margins, and a higher future P/E, informed by recent mixed price target moves and the stock’s inclusion in a 2026 best ideas list. Analyst Commentary Recent Street research around DENTSPLY SIRONA has been mixed, with some analysts trimming price targets while others have made small upward adjustments or highlighted the stock in longer term idea lists.Narrative Update • Feb 06
XRAY: Mixed Execution Risks And Idea List Inclusion Will Shape 2026 Outlook
Narrative Update on DENTSPLY SIRONA The latest analyst price target for DENTSPLY SIRONA has been adjusted in a tight US$1 range, reflecting mixed recent revisions and updated views on growth, profitability, discount rate assumptions and future P/E expectations. The stock continues to appear in some firms' preferred ideas lists.Narrative Update • Jan 23
XRAY: Turnaround Efforts And CFO Changes Will Shape 2026 Recovery Prospects
Analysts have nudged their price target for DENTSPLY SIRONA slightly higher, with fair value moving from about $12.83 to $12.97. This reflects updated assumptions on discount rate, revenue growth, profit margins, and future P/E after recent research that includes both target cuts and a fresh target increase, alongside inclusion in some firms' top ideas lists for 2026.Narrative Update • Jan 08
XRAY: Leadership Turnover And Extended Turnaround Plan Will Shape Recovery Path
Analysts have trimmed their price targets on DENTSPLY SIRONA by about $1, reflecting recent earnings misses, lowered guidance, leadership turnover and a view that any recovery may take longer to play out, even as some still include the stock among broader long term ideas. Analyst Commentary Street research on DENTSPLY SIRONA is split, with some firms still positioning the stock among longer term ideas while others are more focused on near term execution risks and leadership turnover.Narrative Update • Dec 20
XRAY: Longer Turnaround And CFO Transition Will Shape Risk Reward Ahead
The analyst price target for Dentsply Sirona has been reduced from $14 to $11 as analysts factor in softer growth, compressed margins, a higher perceived risk profile, and a longer dated turnaround, partially offset by a higher expected future P E multiple. Analyst Commentary Recent Street research reflects a more cautious stance on Dentsply Sirona, with several bearish analysts trimming price targets and tempering expectations for the pace of any recovery.Narrative Update • Dec 06
XRAY: New Leadership And Turnaround Plan Will Drive Long-Term Recovery Potential
DENTSPLY SIRONA’s analyst price target has been revised modestly lower to $12.96 per share from $13.00, as analysts factor in softer earnings performance, reduced guidance, and ongoing leadership transitions, despite a still constructive long term recovery narrative. Analyst Commentary Analysts are reassessing DENTSPLY SIRONA’s risk reward profile in light of weaker execution, reduced guidance, and leadership turnover, resulting in a cluster of lower price targets and more tempered expectations for the timing of any recovery.Narrative Update • Nov 22
XRAY: Management Shifts And Revised Earnings Guidance Will Drive Long-Term Share Price Recovery
Analysts have lowered their price target for DENTSPLY SIRONA from approximately $16 to around $13. They cite weaker-than-expected earnings, reduced profit margins, and challenges with company guidance as the key factors influencing their decision.Narrative Update • Nov 06
XRAY: Price Target Reductions Will Support Bullish Outlook Despite Sector Headwinds
DENTSPLY SIRONA's analyst price target has been slightly reduced, with recent updates reflecting a new target near $18 to $23. Analysts have incorporated modest changes in fair value and adjusted growth expectations following the latest quarterly results.Narrative Update • Oct 22
Analysts Weigh Mixed Outlook for DENTSPLY SIRONA as Valuation and Guidance Adjusted
Analysts have reduced their price target for DENTSPLY SIRONA from $20 to $18, reflecting adjustments to growth and valuation models after the company's recent quarterly results. Analyst Commentary Bullish Takeaways Bullish analysts note the company's ongoing commitment to refining its operational model, which may lead to improved efficiency over time.Narrative Update • Oct 08
Emerging Markets And Aging Demographics Will Drive Dental Care Demand
Analysts have slightly revised their price targets for DENTSPLY SIRONA, with some lowering expectations by as much as $2 per share. They cite ongoing end-market challenges and updated financial models following recent company results.Analysis Article • Aug 11
DENTSPLY SIRONA (NASDAQ:XRAY) Is Due To Pay A Dividend Of $0.16
The board of DENTSPLY SIRONA Inc. ( NASDAQ:XRAY ) has announced that it will pay a dividend on the 10th of October...Narrative Update • Aug 10
Emerging Markets And Aging Demographics Will Drive Dental Care Demand
Despite an improved revenue growth outlook, a significantly higher discount rate has outweighed this positive, leading to a reduced fair value estimate for DENTSPLY SIRONA, with the consensus analyst price target declining from $18.18 to $17.14. What's in the News Reaffirmed 2025 earnings guidance, expecting net sales of $3.60–$3.70 billion (down 4.0% to 2.0% constant currency), reflecting current tariffs and trade policy.Analysis Article • Jul 22
DENTSPLY SIRONA (NASDAQ:XRAY) Has Some Way To Go To Become A Multi-Bagger
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Analysis Article • May 30
DENTSPLY SIRONA (NASDAQ:XRAY) Will Pay A Dividend Of $0.16
DENTSPLY SIRONA Inc. ( NASDAQ:XRAY ) will pay a dividend of $0.16 on the 7th of July. This means the annual payment is...Analysis Article • May 15
DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) CEO Might Not Expect Shareholders To Be So Generous This Year
Key Insights DENTSPLY SIRONA to hold its Annual General Meeting on 21st of May Total pay for CEO Simon Campion includes...Analysis Article • May 11
Earnings Beat: DENTSPLY SIRONA Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
DENTSPLY SIRONA Inc. ( NASDAQ:XRAY ) just released its latest first-quarter results and things are looking bullish. The...Analysis Article • May 09
DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
DENTSPLY SIRONA Inc. ( NASDAQ:XRAY ) shareholders are no doubt pleased to see that the share price has bounced 26% in...
New Narrative • May 03
Revamped E-commerce And Imaging Products Will Secure Success
Strategic divestment of Wellspect HealthCare aims to unlock value and improve net margins, leveraging its growth and profitability.Analysis Article • Apr 29
Here's Why DENTSPLY SIRONA (NASDAQ:XRAY) Has A Meaningful Debt Burden
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Apr 08
DENTSPLY SIRONA (NASDAQ:XRAY) Has More To Do To Multiply In Value Going Forward
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...Analysis Article • Mar 18
DENTSPLY SIRONA (NASDAQ:XRAY) Has Affirmed Its Dividend Of $0.16
DENTSPLY SIRONA Inc. ( NASDAQ:XRAY ) will pay a dividend of $0.16 on the 11th of April. This makes the dividend yield...Seeking Alpha • Mar 05
Weak Results And Poor Growth Prospects Have Dentsply Sirona Deep In The Street's Doghouse
Summary Dentsply Sirona faces serious growth challenges, as the loss of Byte stings and the company isn't well-leveraged to growth categories in dental care. Q4 results were disappointing, with an 11% organic revenue decline and substantial weakness across all dental business segments, as well as margin contraction. Dentsply is underleveraged to growth categories like implants and aligners, and it's unclear what the company can do to stimulate growth, particularly if capex equipment demand wanes. The valuation is undemanding, even with the assumption of weak revenue growth, but Dentsply shares may struggle to perform so long as revenue growth prospects remain limited. Read the full article on Seeking AlphaAnalysis Article • Feb 13
Benign Growth For DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Underpins Its Share Price
With a price-to-sales (or "P/S") ratio of 0.9x DENTSPLY SIRONA Inc. ( NASDAQ:XRAY ) may be sending very bullish signals...Analysis Article • Jan 08
DENTSPLY SIRONA (NASDAQ:XRAY) Has A Somewhat Strained Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Dec 21
Is Now An Opportune Moment To Examine DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
While DENTSPLY SIRONA Inc. ( NASDAQ:XRAY ) might not have the largest market cap around , it saw significant share...Analysis Article • Dec 03
DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Shares Could Be 40% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, DENTSPLY SIRONA fair value estimate is US$33.10 DENTSPLY...Shareholder Returns
| XRAY | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 6.2% | 5.7% | -0.7% |
| 1Y | -28.9% | -17.8% | 20.3% |
Return vs Industry: XRAY underperformed the US Medical Equipment industry which returned -17.8% over the past year.
Return vs Market: XRAY underperformed the US Market which returned 20.3% over the past year.
Price Volatility
| XRAY volatility | |
|---|---|
| XRAY Average Weekly Movement | 5.6% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: XRAY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: XRAY's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1877 | 14,000 | Dan Scavilla | www.dentsplysirona.com |
DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment offers imaging equipment, motorized dental handpieces, treatment centers, and other instruments; and intraoral scanners, 3-D printers, and mills, as well as CEREC, a full-chairside economical restoration of esthetic ceramic dentistry offering.
DENTSPLY SIRONA Inc. Fundamentals Summary
| XRAY fundamental statistics | |
|---|---|
| Market cap | US$2.44b |
| Earnings (TTM) | -US$628.00m |
| Revenue (TTM) | US$3.68b |
0.6x
P/S Ratio-3.8x
P/E RatioIs XRAY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XRAY income statement (TTM) | |
|---|---|
| Revenue | US$3.68b |
| Cost of Revenue | US$1.88b |
| Gross Profit | US$1.80b |
| Other Expenses | US$2.43b |
| Earnings | -US$628.00m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.13 |
| Gross Margin | 48.93% |
| Net Profit Margin | -17.06% |
| Debt/Equity Ratio | 170.6% |
How did XRAY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/08 21:28 |
| End of Day Share Price | 2026/07/08 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DENTSPLY SIRONA Inc. is covered by 29 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Johnson | Baird |
| Lawrence Marsh | Barclays |
| Glen Santangelo | Barclays |